Vaxcyte appoints John Markels to board as Heath Lukatch retires after 8+ years

Filed July 15, 2026 · Period ending July 13, 2026 · ~1 min read

Key Changes

• medium

  Heath Lukatch retired from the board effective July 16, 2026, after more than eight years of service. The filing states his retirement was not due to any disagreement or dispute with the company.

  Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation verify on EDGAR →
• medium

  John Markels was appointed as a Class II director effective July 16, 2026, with a term through the 2028 annual meeting. He will serve on both the Audit Committee and Compensation Committee.

  Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation verify on EDGAR →
• low

  Dr. Markels qualifies as an independent director under Nasdaq rules and will receive standard non-employee director compensation, including an annual equity grant valued at $430,000.

  Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation verify on EDGAR →